Shares of G1 Therapeutics Plummeted 46% After Phase 3 Trilaciclib Combination Trial Update
Shares of G1 Therapeutics took a significant hit, as they plummeted 46% to $2.44 in after-hours trading on Monday, following the company’s update on its Phase 3 trilaciclib combination trial.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
